Skip to search formSkip to main contentSkip to account menu

K-111

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
This article is part of Ahmed M. Khalid's PhD thesis, which is available in Munin: http://hdl.handle.net/10037/1802 
Review
2007
Review
2007
  • B. Drew, A. Calkin
  • Current opinion in investigational drugs
  • 2007
  • Corpus ID: 45593092
Kozva Co Ltd, under license from Roche Holding AG, is developing K-111, an orally available peroxisome proliferator-activated… 
2004
2004
K-111 has been characterized as a potent peroxisome proliferator-activated receptor (PPAR)alpha activator. Antidiabetic potency… 
2003
2003
K-111, formerly BM 17.0744, (2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid) is a new insulin-sensitizer with peroxisome… 
2002
2002
This study was undertaken to investigate the hypocholesterolemic activity ofBifidobacteria (B. breve K-110,B. breve K-111, andB… 
2001
2001
Panax ginseng is widely used as a Chinese medicine, but it takes a long time to reach harvest and to establish its qualified… 
2000
2000
The antitumor activity ofBifidobacterium breve K-110, and K-111, andB. infantis K-525 was investigated. TheseBifidobacterial… 
1999
1999
The protective effect of Bifidobacterium breve K-110, K-111 and B. infantis K-525 on carbon tetrachloride induced hepatotoxicity… 
1999
1999
Antidiarrheal, anticostive and antimutagenic effects of Bifidobacterium breve K-110, K-111 and B. infantis K-525 isolated from…